Eli Lilly reports positive data from trial of Omvoh for Crohn’s disease

Eli Lilly has revealed that subjects with moderately to severely active Crohn’s disease have achieved long-term clinical and endoscopic outcomes after two years of continuous treatment with Omvoh (mirikizumab-mrkz) in the open-label extension trial, VIVID-2.